Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.38 |
| ▸ | ARG1 | P05089 | 2/20 | 0.37 |
| ▸ | ARG2 | P78540 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL873652 | 0.86 | HSD17B10 (0.42) | HSD17B10ALDH1A1KCNA3 | |
| SCHEMBL167637 | 0.86 | HSD17B10 (0.42) | HSD17B10ALDH1A1KCNA3 | |
| SCHEMBL873557 | 0.86 | HSD17B10 (0.42) | HSD17B10ALDH1A1KCNA3 | |
| SCHEMBL23291292 | 0.81 | HSD17B10 (0.56) | HSD17B10ALDH1A1ITGB3ITGA2BALOX15 | |
| SCHEMBL26986921 | 0.81 | HSD17B10 (0.50) | HSD17B10ALDH1A1ITGB3ITGA2BALOX15 | |
| SCHEMBL8902965 | 0.81 | USP2 (0.42) | USP2ALDH1A1KCNA3ARG1ARG2 | |
| SCHEMBL16228133 | 0.81 | HSD17B10 (0.50) | HSD17B10ALDH1A1ITGB3ITGA2BALOX15 | |
| SCHEMBL835266 | 0.79 | HTT (0.50) | HSD17B10ALDH1A1 | |
| SCHEMBL12640379 | 0.79 | ALDH1A1 (0.41) | USP2ALDH1A1KCNA3TERT | |
| SCHEMBL6215711 | 0.79 | HSD17B10 (0.48) | HSD17B10ITGB3ITGA2BALOX15ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102656179-A | Bufalin derivatives, pharmaceutical compositions and uses thereof | SUZHOU NEUPHARMA CO LTD | 2012-09-05 | — | — | CN | claimed |
| WO-2012027957-A1 | BUFALIN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | SUZHOU NEUPHARMA CO., LTD. (CN) | 2012-03-08 | — | — | WO | claimed |
| CN-1777427-A | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN INC (US) | 2006-05-24 | — | — | CN | claimed |
| US-20260076982-A1 | Prodrugs of Cannbidiol [CBD]-Type Phytocannabinoids and a Process for Preparation Thereof | COUNCIL SCIENT IND RES (IN) | 2026-03-19 | — | — | US | disclosed |
| EP-4551241-A1 | PRODRUGS OF CANNBIDIOL [CBD]-TYPE PHYTOCANNABINOIDS AND A PROCESS FOR PREPARATION THEREOF | Council of Scientific & Industrial Research (IN) | 2025-05-14 | — | — | EP | disclosed |
| US-20250057852-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2025-02-20 | — | — | US | disclosed |
| US-12083124-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| WO-2024009324-A1 | PRODRUGS OF CANNBIDIOL [CBD]-TYPE PHYTOCANNABINOIDS AND A PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024009324-A1 | PRODRUGS OF CANNBIDIOL [CBD]-TYPE PHYTOCANNABINOIDS AND A PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-01-11 | — | — | WO | disclosed |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2023-10-26 | — | — | US | disclosed |
| WO-2023051628-A1 | SOS1 INHIBITORS HAVING PYRIDO SIX-MEMBERED RING STRUCTURE | 上海海和药物研究开发股份有限公司 | 2023-04-06 | — | — | WO | disclosed |
| US-5559232-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1996-09-24 | — | — | US | disclosed |
| US-5484954-A | HEATING, DEACYLATING | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1996-01-16 | — | — | US | disclosed |
| CN-1107839-A | Carbox amide | HOFFMANN LA ROCHE (CH) | 1995-09-06 | — | — | CN | disclosed |
| EP-0641779-A1 | Novel 1-amidinopiperdines and 4-amidinomorpholines as aggregation inhibitions | F. HOFFMANN-LA ROCHE AG (CH) | 1995-03-08 | — | — | EP | disclosed |
| US-5302730-A | Acylation with acetic acid at positions one and seven; eliminating acyl group at position seven by solvolysis | NIPPON KAYAKU KK (JP) | 1994-04-12 | — | — | US | disclosed |
| EP-0297496-B1 | Novel process for the preparation of 6,7-Diacyl-7-deacetylforskolin derivatives | NIPPON KAYAKU KK (JP) | 1994-01-19 | — | — | EP | disclosed |
| US-5245052-A | PROCESS FOR PRODUCING 6-ACYL-7-DEACETYLFORSKOLIN DERIVATIVES | NIPPON KAYAKU CO. LTD. (JP) | 1993-09-14 | — | — | US | disclosed |
| EP-0469428-A1 | Novel process for producing 6-acyl-7-deacetylforskolin derivatives | HOECHST JAPAN LIMITED (JP) | 1992-02-05 | — | — | EP | disclosed |
| EP-0297496-A2 | Novel process for the preparation of 6,7-Diacyl-7-deacetylforskolin derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1989-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12083124-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | HSD17B10 159/4885USP2 4138/4885ALDH1A1 559/4885 |
| US-20260076982-A1 | Prodrugs of Cannbidiol [CBD]-Type Phytocannabinoids and a Process for Preparation Thereof | CNR1, CNR2, CBR1 | HSD17B10 208/4885USP2 2638/4885ALDH1A1 1408/4885 |
| US-20250057852-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | HSD17B10 159/4885USP2 4138/4885ALDH1A1 559/4885 |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | HSD17B10 159/4885USP2 4138/4885ALDH1A1 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.